Lohith Gowda, MD, MRCP
Assistant Professor of Medicine (Hematology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Assistant Professor of Medicine (Hematology), Internal Medicine
About
Titles
Assistant Professor of Medicine (Hematology)
Assistant Professor of Medicine (Hematology), Internal Medicine
Biography
Curing hematologic cancers with precision medicine and minimal toxicity has been a multigeneration challenge and a highly prioritized work for our group at Yale. Through continual engagement with patients and their families, educational meetings and well informed decision making sessions, we help our patients navigate the field of transplantation and cellular therapy. Our multidisciplinary team while trying to harness the curative promise of cellular immunotherapy also has special focus to enhance its safety and provide long term supervision for cancer survivors. We strongly encourage our patients to learn the strengths and limitations of the existing standard of care, the knowledge of which could be applied to personalize treatment plans and foster research environment to advance the broader field.
Last Updated on April 07, 2025.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Hematology
- Internal Medicine
- Medical Oncology and Hematology
- Yale Cancer Center
- Yale Center for Immuno-Oncology
- Yale CTAP
- Yale Medicine
Education & Training
- Advanced Fellowship
- MD Anderson Cancer Center (2017)
- Advanced Fellowship
- NY Presbyterian Cornell/New York Blood Center (2016)
- Fellowship
- Albert Einstein College of Medicine (2014)
- Internship/Residency
- Drexel University College of Medicine (2011)
- General Medicine Trainee
- National Health Service UK (2008)
- MD
- Rajiv Gandhi University (2004)
Research
Overview
Targeted therapy; Transfusion Associated Immunomodulation, Immunotherapy, Cellular Therapy, Regenerative Medicine
Medical Research Interests
Anemia, Aplastic; Blood Transfusion; Bone Marrow Diseases; Hematopoietic Stem Cell Transplantation; Immunotherapy; Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis
ORCID
0009-0001-1726-9749
Research at a Glance
Yale Co-Authors
Frequent collaborators of Lohith Gowda's published research.
Publications Timeline
A big-picture view of Lohith Gowda's research output by year.
Research Interests
Research topics Lohith Gowda is interested in exploring.
Stuart Seropian, MD
Francine Foss, MD
Iris Isufi, MD
Noffar Bar, MD
Nikolai Podoltsev, MD, PhD
Jan Philipp Bewersdorf, MD, FACP
95Publications
884Citations
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Blood Transfusion
Primary Myelofibrosis
Leukemia
Multiple Myeloma
Publications
2025
Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR
Wudhikarn K, Herr M, Chen M, Martens M, Baird J, Gowda L, Rangarajan H, Abid M, Kharfan-Dabaja M, Williams K, Ganguly S, Young J, Sharma A, Fatobene G, Jain T, Kanakry C, Modi D, Grover N, Salem B, Batista M, Vergidis P, Yin D, Beitinjaneh A, Kelkar A, Nishihori T, Holter-Chakrabarty J, Gergis U, Smith M, El Boghdadly Z, Dandoy C, Murthy H, Huppler A, Perales M, Chemaly R, Hill J, Riches M, Auletta J. Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR. Blood Advances 2025 PMID: 40435511, DOI: 10.1182/bloodadvances.2025016141.Peer-Reviewed Original ResearchAltmetricConceptsCD19 chimeric antigen receptorT-cell therapyCD19 chimeric antigen receptor T-cell therapyInfection-related mortalityCD19 CAR-T cellsCAR-T cellsT cellsSevere immune effector cell-associated neurotoxicity syndromeChimeric antigen receptor T-cell therapyImmune effector cell-associated neurotoxicity syndromeCD19 CAR T-cell therapyCAR-T cell therapySevere cytokine release syndromeRisk factorsChimeric antigen receptorInferior overall survivalMedian follow-upB-cell lymphomaCytokine release syndromeIndependent risk factorCause of morbidityDays post-infusionIncidence of infectionOutcome of infectionIncreased infection riskImpact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant
VanOudenhove J, Liu Y, Nelakanti R, Kim D, Busarello E, Ovalle N, Qi Z, Mamillapalli P, Siddon A, Bai Z, Axtmayer A, Corso C, Kothari S, Foss F, Isufi I, Tebaldi T, Gowda L, Fan R, Seropian S, Halene S. Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant. PLOS ONE 2025, 20: e0320744. PMID: 40294012, PMCID: PMC12036906, DOI: 10.1371/journal.pone.0320744.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsHematopoietic stem cell transplantationMemory T cellsStem cell transplantationCell transplantationT cellsSARS-CoV-2Hematopoietic stem cell transplant recipientsAntigen-specific T-cell activationSARS-CoV-2 mRNA vaccinesSARS-CoV-2 vaccine responsesSevere diseaseAnti-spike IgGT cell activationAdaptive immune responsesRobust antibody responsesPost-vaccination responseSARS-CoV-2 infectionMRNA vaccine seriesSingle-cell RNAMyeloablative chemotherapyCellular responsesImmune profileVaccine responseCOVID-19 infectionMRNA vaccinesTeduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey
Brehm N, Biavasco F, Clausen J, Jung J, Maas-Bauer K, Wäsch R, Verbeek M, Nuernbergk C, Ihorst G, Seropian S, Finke J, Gowda L, Sidlik Muskatel R, Peffault de Latour R, Socie G, Wehr C, Michonneau D, Zeiser R. Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey. Bone Marrow Transplantation 2025, 60: 873-878. PMID: 40229535, PMCID: PMC12151853, DOI: 10.1038/s41409-025-02586-2.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsGlucagon-like peptide-2Non-relapse mortalityIntestinal acute graft-versus-host diseaseLevels of glucagon-like peptide-2Acute graft-versus-host diseaseGraft-versus-host diseaseMulticenter surveyAllogeneic hematopoietic cell transplantationRetrospective multicenter surveyHematopoietic cell transplantationFraction of patientsAlbumin serum levelsIntestinal stem cellsGVHD severitySR-aGVHDTeduglutide treatmentAcute GVHDAllo-HCTCell transplantationProspective trialsPreclinical dataSerum levelsTreated patientsRetrospective analysisFollow-upStandard of Care Idecabtagene Vicleucel (Ide-cel) for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
Sidana S, Ahmed N, Akhtar O, Brazauskas R, Oloyede T, Bye M, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Landau H, Mirza A, Patwardhan P, Qazilbash M, Usmani S, Patel K, Nishihori T, Ganguly S, Pasquini M. Standard of Care Idecabtagene Vicleucel (Ide-cel) for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis. Blood 2025 PMID: 40198886, DOI: 10.1182/blood.2024026216.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCAR-T cell therapyStandard of careIde-celComplete responseIdecabtagene vicleucelMultiple myelomaImmune effector cell-associated neurotoxicity syndromeClinical trialsMedian progression-free survivalHigh-risk cytogeneticsProgression-free survivalT-cell therapyTreatment-related mortalityRelapsed/refractory multiple myelomaMedian follow-upClinically significant infectionsCytokine release syndromeSignificant co-morbiditiesSignificant co-morbidityEffects of standard of careExtramedullary diseaseCAR-TMyeloid malignanciesPrimary malignancyMedian ageOutcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
Akhtar O, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen D, Ferreri C, Dhakal B, Dhanda D, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Gowda L, Anderson L, Pasquini M, Usmani S, Freeman C. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Advances 2025, 9: 1587-1592. PMID: 39786391, PMCID: PMC11986210, DOI: 10.1182/bloodadvances.2024014970.Peer-Reviewed Original ResearchAltmetricUS Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines
Munshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, Bhatt V, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton B, Inamoto Y, Jayani R, Kharfan-Dabaja M, Lin R, Meyers G, Mishra A, Murthy H, Nawas M, Rosko A, Ruiz M, Sorror M, Sung A, Carpenter P, Hamadani M, Artz A. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplantation And Cellular Therapy 2025, 31: 285-296. PMID: 39961473, DOI: 10.1016/j.jtct.2025.02.014.Peer-Reviewed Original ResearchAltmetricConceptsHematopoietic cell transplantationT-cell therapyCAR-T cell therapyCAR-TCell transplantationGeriatric assessmentCellular therapyChimeric antigen T-cell therapyAmerican Society for TransplantationPromote risk stratificationAllo-HCTRisk stratificationCell therapyOlder patientsRoutine GAOlder adultsGa uptakeTherapyPhysician practice patternsTransplantationPractice patternsClinical support staffCross-sectional surveyPhysician membersDomain of GATSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910)
Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Pineiro L, Gill S, Gowda L, Uberti J, White T, Wang Y, Nguyen C, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation And Cellular Therapy 2025, 31: s59-s60. DOI: 10.1016/j.jtct.2025.01.096.Peer-Reviewed Original ResearchConceptsRIC HCTReduced intensity conditioningHematopoietic cell transplantationRelapse-free survivalPost-HCTControl subjectsControl armDonor chimerismGrade II-IV acute graft-versus-host diseaseII-IV acute graft-versus-host diseaseT cell receptor-engineered T cellsAcute graft-versus-host diseasePhase 1 dose-escalation studyIncreased relapse-free survivalGraft-versus-host diseaseAllogeneic hematopoietic cell transplantationNon-relapse deathPost-HCT MRDEngineered T cellsCytokine release syndromeData cut-offMonths post-HCTReducing relapse ratesYears post-HCTAssessment of efficacyOutcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience
Taborda C, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. Outcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience. Transplantation And Cellular Therapy 2025, 31: s393-s394. DOI: 10.1016/j.jtct.2025.01.606.Peer-Reviewed Original ResearchConceptsAcute graft-versus-host diseaseReduced-intensity conditioningGraft-versus-lymphomaNon-relapse mortalityPosttransplant cyclophosphamideT-cell lymphomaAllo-SCTOverall survivalGVHD prophylaxisT cellsAssociated with improved overall survivalTacrolimus-based GVHD prophylaxisAllogeneic stem cell transplantationGraft-versus-host diseaseAggressive T-cell lymphomaT-cell lymphoma patientsHaplo-identical transplantationReduced intensity conditioningImproved overall survivalRelapse-free survivalMedian follow-upSingle-center experienceReduce treatment toxicityStem cell transplantationSingle institution experience
2024
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants
Nishino J, Hu W, Kishtagari A, Shen B, Gao X, Blackman C, Kassim A, Marneni N, Cherukuri A, Vittrup R, Kalkan F, Shah R, Ahn C, Gao A, Ahmedrabie A, Collins R, Zeidan A, Bidikian A, Gowda L, Shaffer B, Madanat Y, Zhao Z, Chung S, Morrison S. Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants. Cancer Discovery 2024, 15: 748-766. PMID: 39786370, PMCID: PMC11962394, DOI: 10.1158/2159-8290.cd-24-0719.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationB-blockersCell transplantationHematopoietic regenerationGraft-versus-host disease prophylaxisAutologous hematopoietic cell transplantationDelayed platelet engraftmentImpaired hematopoietic regenerationPost-transplant chemotherapyGraft-versus-hostAdrenergic receptor signalingBone marrow regenerationInhibitory effectPlatelet engraftmentInhibit engraftmentReceptor inhibitorsDisease prophylaxisMarrow regenerationMouse hematopoiesisHematopoietic cellsEngraftmentLarger dosesReceptor signalingPeripheral nervesTSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial
Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Gill S, Gowda L, Uberti J, Buonomo E, Wang Y, Nabilsi N, White T, Nguyen C, Murray J, MacBeath G, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial. Blood 2024, 144: 924. DOI: 10.1182/blood-2024-201526.Peer-Reviewed Original ResearchConceptsReduced intensity conditioningRelapse-free survivalPost-HCTDonor chimerismTreatment armsFollow-upControl armMalignant lineagesGrade 2-4 acute graft-versus-host diseaseT cell receptor-engineered T cellsControl subjectsIncreased relapse-free survivalGraft-versus-host diseaseMedian time to relapseControl arm subjectsNon-relapse deathPost-HCT MRDComplete donor chimerismDonor-derived cellsEngineered T cellsMedian follow-upTime to relapseCD3+ cellsPhase 1 studyARMS subjects
Clinical Trials
Current Trials
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
HIC ID2000028478RoleSub InvestigatorPrimary Completion Date07/30/2023Recruiting ParticipantsA Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies
HIC ID2000027145RoleSub InvestigatorPrimary Completion Date09/28/2028Recruiting ParticipantsManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
HIC ID2000025634RoleSub InvestigatorPrimary Completion Date07/06/2023Recruiting Participants
Academic Achievements & Community Involvement
Activities
activity American Society of Oncology
2011 - PresentProfessional OrganizationsMemberactivity American Society of Hematology
2011 - PresentProfessional OrganizationsMemberactivity Yale Stem Cell Transplant QI Committee
2018 - PresentProfessional OrganizationsMemberactivity YCC Data Safety Monitoring Committee
2019 - PresentProfessional OrganizationsMemberactivity American Society for Blood and Marrow Transplantation
2017 - PresentProfessional OrganizationsMember
Honors
honor DAVID S FISHER Annual Award
06/14/2023Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor American Society of Hematlogy Abstract Achievement Award
10/02/2017National AwardDetailsUnited Stateshonor Academy of Clinical Laboratory Physicians and Scientists-Paul E. Strandjord Young Investigator Award
12/01/2016National AwardDetailsUnited Stateshonor American Association of Blood Banks-Fenwal Scholarship
12/01/2015National AwardDetailsUnited Stateshonor Drexel Discovery Day Research Award
09/30/2009Regional AwardDrexel University College of MedicineDetailsUnited States
Clinical Care
Overview
Lohith Gowda, MD, is a hematologist, which means he studies and treats blood-based diseases and cancers including leukemia and bone marrow failure.
Dr. Gowda’s team includes not just other doctors and scientists but patients and their families. The team meets often to help patients and families navigate the complexities of stem-cell transplant and cellular therapy, all of which are involved in the treatment of blood-based diseases. It is important for patients and families to fully understand options for care in order to make informed decisions, he says.
An active researcher, Dr. Gowda’s work examines the effectiveness of specific strategies for treating blood disorders, as well as their effects on patients’ well-being and long-term care. While transplantation may give patients a new lease on life, dedicated follow-up care for transplant recipients is vital, Dr. Gowda says.
Dr. Gowda is a member of the Royal College of Physicians and has received many awards, including the Young Investigator Award from the Academy of Clinical Laboratory Physicians and Scientists and the American Society of Hematology’s Abstract Achievement Award.
Clinical Specialties
Hematology
Fact Sheets
Acute Myeloid Leukemia (AML)
Learn More on Yale MedicineCAR T-Cell Therapy
Learn More on Yale MedicineMyeloproliferative Neoplasms
Learn More on Yale MedicineMyelodysplastic/Myeloproliferative Neoplasms
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.